ABVC BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ABVC BIOPHARMA, INC. (Nasdaq: ABVC) on May 15, 2024, reporting events occurring on May 14, 2024. The filing details the entry into a material definitive agreement regarding the licensing of a botanical drug extract.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The only financial figures disclosed relate to the new licensing agreement:
- Total Consideration: $6,250,000 (payable in cash or 1,250,000 OncoX shares valued at $5.00 per share).
- Payment Timing: Due 30 days after the agreement date.
- Milestone Payment: Additional $625,000 in cash contingent on OncoX's next fundraising round.
- Royalties: 5% of Net Sales from the first commercial sale in the licensed territory.
Material Changes
The primary material change is the execution of the "Oncox Agreement" with OncoX BioPharma, Inc. Key terms include:
- Licensed Product: BLEX 404, a single-herb botanical drug extract from Maitake Mushroom for Triple Negative Breast Cancer.
- Scope: Exclusive right to develop and commercialize within 50% of Worldwide Markets.
- Duration: 20 years.
- Flexibility: OncoX may pay in installments or lump sum and use revenue to fund payments. OncoX may also remit cash payments of at least $100,000 towards licensing fees, deductible from the second milestone.
- Affiliate Agreement: OncoX entered into a similar agreement with ABVC's affiliate, Biolite, Inc.
Outlook, Risks, and Contingencies
Management commentary and risk factors highlighted in the filing include:
- Fundraising Contingency: The $625,000 milestone payment is contingent on OncoX's next round of fundraising, which the filing explicitly states "there can be no guarantee" of.
- Commercial Uncertainty: The filing notes that the first commercial sale of the Licensed Product in the noted territory "remains uncertain."
- Valuation Note: The $5.00 per share valuation for OncoX stock was determined through private negotiations; no third-party valuation was completed.
- Regulatory Status: The securities mentioned in the agreement have not been registered under the U.S. Securities Act of 1933.
Investor Verification Checklist
- Verify the financial stability and fundraising status of OncoX BioPharma, Inc. to assess the likelihood of the $625,000 milestone payment.
- Review the full text of the Definitive License Agreement (Exhibit 10.1) for detailed definitions of "Net Sales" and payment installment terms.
- Confirm the regulatory status and development timeline of the BLEX 404 extract for Triple Negative Breast Cancer.
- Assess the impact of the affiliate agreement with Biolite, Inc. on ABVC's overall portfolio strategy.